Who are Antivert's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antivert, Dilantin, Zocor, Restoril, Zofran, Motilium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/meclozine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Antivert — Competitive Intelligence Brief

Antivert (meclozine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiemetic. Area: Other.

marketed Antiemetic Nuclear receptor subfamily 1 group I member 3 Other Live · refreshed every 30 min

Target snapshot

Antivert (meclozine) — Citron Pharma Llc.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antivert TARGET	meclozine	Citron Pharma Llc	marketed	Antiemetic	Nuclear receptor subfamily 1 group I member 3	1957-01-01
Antivert	meclizine	Generic (originally Pfizer/UCB)	marketed	Antihistamine/Antiemetic (vestibular suppressant)	Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor	1957-01-01
Dilantin	Phenytoin Sodium	Pfizer	marketed	phenytoin	Nuclear receptor subfamily 1 group I member 3	1953-01-01
Zocor	simvastatin	Merck & Co.	marketed	HMG-CoA Reductase Inhibitor [EPC]	Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Restoril	temazepam	Mallinckrodt	marketed	Benzodiazepine [EPC]	Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2
Zofran	ondansetron	GSK (originally Glaxo)	marketed	5-HT3 receptor antagonist (antiemetic)	Aldehyde oxidase, 5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1	1991-01-04
Motilium	domperidone	Johnson & Johnson (Janssen)	marketed	Prokinetic agent / Antiemetic	Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2	1978-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-26 — Zocor · 10300041 · Formulation · US
2029-11-23 — Zofran · 8580830 · Formulation · US
2030-02-23 — Zocor · 9597289 · Formulation · US
2030-07-13 — Zofran · 9095577 · Formulation · US

Sponsor landscape (Antiemetic class)

· 1 drug in this class
Citron Pharma Llc · 1 drug in this class
Newark Beth Israel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antivert — Competitive Intelligence Brief. https://druglandscape.com/ci/meclozine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab